Eli Lilly and Company
COMBINATION THERAPY
Last updated:
Abstract:
A method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-N3pGlu Abeta antibody, an anti-Abeta antibody, or an antibody fragment that binds Amyloid beta and is covalently attached to a polyethylene glycol molecule, in combination with an effective amount of an anti-Tau antibody.
Status:
Application
Type:
Utility
Filling date:
24 Mar 2021
Issue date:
30 Sep 2021